Latest news with #FightCRC
Business Upturn
3 days ago
- Business
- Business Upturn
First Ascent Biomedical and Fight Colorectal Cancer Announce Groundbreaking Study to Advance Precision Oncology for Colorectal Cancer Patients
By GlobeNewswire Published on June 6, 2025, 23:41 IST Springfield, Mo., June 06, 2025 (GLOBE NEWSWIRE) — First Ascent Biomedical (FA), an innovative biotech company specializing in transforming cancer treatment through functional precision medicine, is proud to announce a new collaboration with national nonprofit Fight Colorectal Cancer (Fight CRC) to launch a prospective feasibility study aimed at transforming colorectal cancer treatment. Funded by a $350,000 grant from Fight CRC, and spearheaded by Anjee Davis, chief executive officer, this innovative study will leverage First Ascent's cutting-edge xDRIVE tumor profiling technology to deliver rapid, personalized treatment insights for patients fighting colon cancer in Minnesota. 'Fight CRC is committed to empowering patients through innovation,' said Davis. 'This grant underscores our strategic focus on enhancing care through advanced research, particularly for those with limited treatment options.' The study, set to begin enrollment in April or May 2025, will focus on 25 patients with metastatic colorectal cancer. By integrating functional drug testing, genetic analysis, and artificial intelligence, First Ascent's xDRIVE platform will provide oncologists with detailed tumor profiling data and tailored treatment options, aiming to enhance patient outcomes. Leading the clinical efforts are Hao Xie, MD, PhD, a gastrointestinal cancer specialist and precision medicine expert, and Dr. Boardman, whose work in cancer genetics and early detection has advanced the field of colorectal cancer care. Noah Berlow, PhD, First Ascent's Chief Technology Officer and the study's principal investigator, brings his expertise in AI-driven cancer research to oversee the project. Together, this team is poised to demonstrate the power of rapid, individualized tumor profiling to better understand each patient's unique cancer. 'This collaboration with Fight Colorectal Cancer is another important step in transforming how we approach cancer treatment,' said Jim Foote, founder and chief executive officer, First Ascent Biomedical. 'We are honored to be part of this effort.' The study is expected to complete enrollment within nine months and will provide actionable data to oncologists for patients requiring advanced treatment options. Patients interested in participating must be seen in Rochester, MN. Information will soon be available on Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
3 days ago
- Health
- Yahoo
First Ascent Biomedical and Fight Colorectal Cancer Announce Groundbreaking Study to Advance Precision Oncology for Colorectal Cancer Patients
Springfield, Mo., June 06, 2025 (GLOBE NEWSWIRE) -- First Ascent Biomedical (FA), an innovative biotech company specializing in transforming cancer treatment through functional precision medicine, is proud to announce a new collaboration with national nonprofit Fight Colorectal Cancer (Fight CRC) to launch a prospective feasibility study aimed at transforming colorectal cancer treatment. Funded by a $350,000 grant from Fight CRC, and spearheaded by Anjee Davis, chief executive officer, this innovative study will leverage First Ascent's cutting-edge xDRIVE tumor profiling technology to deliver rapid, personalized treatment insights for patients fighting colon cancer in Minnesota. 'Fight CRC is committed to empowering patients through innovation,' said Davis. 'This grant underscores our strategic focus on enhancing care through advanced research, particularly for those with limited treatment options.' The study, set to begin enrollment in April or May 2025, will focus on 25 patients with metastatic colorectal cancer. By integrating functional drug testing, genetic analysis, and artificial intelligence, First Ascent's xDRIVE platform will provide oncologists with detailed tumor profiling data and tailored treatment options, aiming to enhance patient outcomes. Leading the clinical efforts are Hao Xie, MD, PhD, a gastrointestinal cancer specialist and precision medicine expert, and Dr. Boardman, whose work in cancer genetics and early detection has advanced the field of colorectal cancer care. Noah Berlow, PhD, First Ascent's Chief Technology Officer and the study's principal investigator, brings his expertise in AI-driven cancer research to oversee the project. Together, this team is poised to demonstrate the power of rapid, individualized tumor profiling to better understand each patient's unique cancer. 'This collaboration with Fight Colorectal Cancer is another important step in transforming how we approach cancer treatment,' said Jim Foote, founder and chief executive officer, First Ascent Biomedical. 'We are honored to be part of this effort.' The study is expected to complete enrollment within nine months and will provide actionable data to oncologists for patients requiring advanced treatment options. Patients interested in participating must be seen in Rochester, MN. Information will soon be available on CONTACT: Savanna Doud Fight Colorectal Cancer 703.548.1225 savanna@ in to access your portfolio
Yahoo
27-05-2025
- General
- Yahoo
Global Experts from 23 Countries Convene in Barcelona to Confront Rising Rates of Early Onset Colorectal Cancer
Global Early Onset Colorectal Cancer Think Tank Springfield, Mo., May 27, 2025 (GLOBE NEWSWIRE) -- Fight Colorectal Cancer (Fight CRC), in partnership with Dr. José Perea of the Instituto de Investigación Biomédica de Salamanca (IBSAL) and a global network of collaborators, will host the inaugural Global Early Onset Colorectal Cancer Think Tank (GEOCRCTT) on June 18–19 in Barcelona, Spain. This two-day event will convene leading experts from research, healthcare, and advocacy to develop a comprehensive research strategy aimed at reversing the troubling trend in early onset colorectal cancer (EOCRC) cases. 'It's the first time we've ever hosted an international meeting, and we are thrilled to convene more than 75 scientists and patients,' said Anjee Davis, CEO of Fight CRC. 'Global partners consistently ask us, 'How can we meaningfully engage patients and reflect their voices in the science?' Through this international coalition of scientists, we're committed to advancing the science with patients at the center. We want to make sure the lessons we've learned in the U.S. are shared globally. This isn't just about presenting research; it's about rolling up our sleeves and working together to drive it forward. It's a true dialogue around collaboration, and that level of global partnership simply hasn't happened before.' As early onset colorectal cancer becomes increasingly prevalent, especially in countries with traditionally lower risk, the GEOCRCTT represents a timely and necessary response. Through keynote speeches, interactive panel discussions, and specialized breakout sessions, the Think Tank will facilitate knowledge sharing across borders and disciplines. Experts will focus on setting research priorities, strengthening collaborative efforts, and identifying targeted ways to support patients, caregivers, and affected communities worldwide. 'This gathering marks a pivotal moment in our approach to early onset colorectal cancer research as one of the only initiatives to explore global etiology; not just from a specific country or region, the entire world,' said Andrea (Andi) Dwyer, advisor to Fight CRC and member of the University of Colorado Cancer Center. "The future of EOCRC research and patient support depends on this level of unity and commitment.' The GEOCRCTT reflects the growing urgency to address EOCRC with a united, strategic approach. For more information on the GEOCRCTT, or to support Fight Colorectal Cancer and its partners, visit or join the conversation at #GEOCRCTT. GEOCRCTT Goals and Deliverables: Publishing Think Tank Outcomes: Findings, recommendations, and action items will be published in a leading peer-reviewed journal, making them accessible to the global research and medical communities. Supporting Critical Research Efforts: Through GEOCRCTT, six grants have been awarded to support baseline data collection internationally. This research funding underscores a united commitment to filling gaps in understanding EOCRC's causes, risk factors, and trends on an international scale. Empowering Patients and Advocates: Through focused sessions, GEOCRCTT will provide advocacy groups and patient communities with the latest information and strategies to elevate awareness and improve support networks globally. Fight CRC remains committed to advancing these efforts and fostering a global culture of informed, patient-centered care. Attachment Global Early Onset Colorectal Cancer Think Tank CONTACT: Savanna Doud Fight Colorectal Cancer 703-548-1225 media@
CBS News
24-03-2025
- Health
- CBS News
North Texas woman advocates for colon cancer awareness in young adults in memory of her brother
March is Colon Cancer Awareness Month – a time to stress the importance of education and screenings, especially for young adults in their 20s and 30s. While there is no one-size-fits-all explanation for why millennials are at a higher risk, Jenna White, of Keller, is making it her mission to carry out her brother's legacy. Evan White died from colon cancer days before his 29th birthday. "He was really good about, you know, putting on a smile for everyone else, so just to be there and see kind of behind the scenes of what cancer treatment is really like and how difficult it was really eye-opening," Jenna White, Evan's sister, said. Evan White's family and friends wear blue to support a cause that's near and dear to them. Each year they host an annual golf tournament and bar crawl in honor of Evan and Colorectal Cancer Awareness Month. This March, Evan's family and friends raised $67,000 during their annual fundraiser and set a new record. "He was diagnosed at the age of 24 and so that was quite the shock to the family because we had no family history," White said. More than a fighter of one of the top three deadliest cancers, Evan loved to travel, music, and his dog Lola, his companion through cancer treatment. "People always said like, 'Oh, he's just like his dog Lola,' just like always happy always carefree despite, you know, everything," White said. Jenna White is now an ambassador for the non-profit organization, FightCRC, and travels from Fort Worth to D.C. to advocate for funding and research for colon cancer. This month, a sea of more than 27,000 blue flags waved outside the U.S. Capitol. Each flag represents a young adult under 50 who will be diagnosed with colorectal cancer by 2030. "Evan was a big advocate and so now, like that's something I'm really passionate about too, just because it is such a difficult thing for not only the person, who's sick, but you know, their family, their loved ones and friends to all go through it together," White said. White said colorectal cancer is the only top five cancer killer without its own research program and funding. "Just because Evan's not here, doesn't mean his fight's over. And we can keep his fight going… and we'll continue to fight, you know, for those who aren't here… so that their fight, you know, wasn't in vain," White said. Doctors said colon cancer is on the rise in people in their 20s and 30s and recommend annual screenings and being aware of symptoms — constipation, blood in your stool, sudden changes in bowel habits and abnormal weight loss.
